June 05, 2023
3 min watch
Save
VIDEO: Phase 3 data promising for iDose TR
Key takeaways:
- There were no significant issues with endothelial cell loss.
- No adverse events have been seen in exchange studies with the iDose TR.
SAN DIEGO — In this Healio Video Perspective from the ASCRS meeting, I. Paul Singh, MD, discusses phase 3 data on the iDose TR implant from Glaukos.
“Not only did we get 8.5 mm Hg reduction in IOP, we actually found out it was superior to that of topical [prostaglandin analog],” he said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Singh reports speaking and consulting for Glaukos.
Read more about